Literature DB >> 19399007

Pulmonary surfactant kinetics of the newborn infant: novel insights from studies with stable isotopes.

V P Carnielli1, L J I Zimmermann, A Hamvas, P E Cogo.   

Abstract

Deficiency or dysfunction of the pulmonary surfactant plays a critical role in the pathogenesis of respiratory diseases of the newborn. After a short review of the pulmonary surfactant, including its role in selected neonatal respiratory conditions, we describe a series of studies conducted by applying two recently developed methods to measure surfactant kinetics. In the first set of studies, namely 'endogenous studies', which used stable isotope-labeled intravenous surfactant precursors, we have shown the feasibility of measuring surfactant synthesis and kinetics in infants using several metabolic precursors, including plasma glucose, plasma fatty acids and body water. In the second set of studies, namely 'exogenous studies', which used a stable isotope-labeled phosphatidylcholine (PC) tracer given endotracheally, we estimated the surfactant disaturated phosphatidylcholine (DSPC) pool size and half-life. The major findings of our studies are presented here and can be summarized as follows: (a) the de novo synthesis and turnover rates of the surfactant (DSPC) in preterm infants with respiratory distress syndrome (RDS) are very low with either precursor; (b) in preterm infants with RDS, pool size is very small and half-life much longer than what has been reported in animal studies; (c) patients recovering from RDS who required higher continuous positive airway pressure pressure after extubation or reintubation have a lower level of intrapulmonary surfactant than those who did well after extubation; (d) term newborn infants with pneumonia have greatly accelerated surfactant catabolism; and (e) infants with uncomplicated congenital diaphragmatic hernia (CDH) and on conventional mechanical ventilation have normal surfactant synthesis, but those requiring extracorporeal membrane oxygenated (ECMO) do not. Information obtained from these studies in infants will help to better tailor exogenous surfactant treatment in neonatal lung diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399007     DOI: 10.1038/jp.2009.32

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  7 in total

1.  In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.

Authors:  Francesca Ricci; Xabier Murgia; Roberta Razzetti; Nicola Pelizzi; Fabrizio Salomone
Journal:  Pediatr Res       Date:  2016-11-03       Impact factor: 3.756

2.  Apolipoprotein C-II and lipoprotein lipase show a temporal and geographic correlation with surfactant lipid synthesis in preparation for birth.

Authors:  Mélissa Côté; Pierre R Provost; Marie-Christine Gérard-Hudon; Yves Tremblay
Journal:  BMC Dev Biol       Date:  2010-11-08       Impact factor: 1.978

3.  The pharmacology of acute lung injury in sepsis.

Authors:  Brian Michael Varisco
Journal:  Adv Pharmacol Sci       Date:  2011-06-28

4.  Physical properties of phospholipids and integral proteins and their biofunctional roles in pulmonary surfactant from molecular dynamics simulation.

Authors:  Nourddine Hadrioui; Mohammed Lemaalem; Abdelali Derouiche; Hamid Ridouane
Journal:  RSC Adv       Date:  2020-02-27       Impact factor: 4.036

5.  Dose Effect of Poractant Alfa in Neonatal RDS: Analysis of Combined Data from Three Prospective Studies.

Authors:  Barbara Królak-Olejnik; Roman Hożejowski; Tomasz Szczapa
Journal:  Front Pediatr       Date:  2020-11-24       Impact factor: 3.418

6.  Respiratory distress syndrome in preterm infants of less than 32 weeks: What difference does giving 100 or 200 mg/kg of exogenous surfactant make?

Authors:  Lucia Lanciotti; Alessio Correani; Matteo Pasqualini; Luca Antognoli; Valentina G Dell'Orto; Chiara Giorgetti; Sara Colombo; Maria L Palazzi; Clementina Rondina; Ilaria Burattini; Virgilio P Carnielli
Journal:  Pediatr Pulmonol       Date:  2022-05-27

Review 7.  Clinical review: Exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome--where do we go from here?

Authors:  Ahilanandan Dushianthan; Rebecca Cusack; Victoria Goss; Anthony D Postle; Mike P W Grocott
Journal:  Crit Care       Date:  2012-11-22       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.